Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
5.11
-0.15 (-2.85%)
At close: Apr 1, 2026, 4:00 PM EDT
5.11
0.00 (0.00%)
After-hours: Apr 1, 2026, 4:00 PM EDT
Atossa Therapeutics Employees
Atossa Therapeutics had 15 employees as of December 31, 2024. The number of employees increased by 3 or 25.00% compared to the previous year.
Employees
15
Change (1Y)
3
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,318,000
Market Cap
44.00M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 15 | 3 | 25.00% | 15 | 0 |
| Dec 31, 2023 | 12 | 1 | 9.09% | 12 | 0 |
| Dec 31, 2022 | 11 | 3 | 37.50% | 11 | 0 |
| Dec 31, 2021 | 8 | 0 | - | 6 | 2 |
| Dec 31, 2020 | 8 | 2 | 33.33% | 6 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Xilio Therapeutics | 64 |
| Lisata Therapeutics | 21 |
| Edesa Biotech | 17 |
| Rallybio | 14 |
| Nutriband | 13 |
| RenovoRx | 10 |
| Telomir Pharmaceuticals | 9 |
ATOS News
- 6 days ago - Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 13 days ago - Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives - PRNewsWire
- 20 days ago - Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference - PRNewsWire
- 7 weeks ago - Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook - PRNewsWire
- 7 weeks ago - Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program - PRNewsWire
- 2 months ago - Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 - PRNewsWire
- 2 months ago - Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy - PRNewsWire
- 3 months ago - Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer - PRNewsWire